This article is more than 5 years old. Information may no longer be current.

EyeGate randomizes first patients in punctate epitheliopathies study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals has randomized the first three patients in a study of its Ocular Bandage Gel to reduce corneal staining in punctate epitheliopathies, the company announced in a press release.

Thirty-four subjects are currently in the qualification stage before randomization; subjects are still being enrolled in the study because 30 patients are needed for the treatment stage.

The Ocular Bandage Gel is also being studied in patients with large corneal defects due to PRK surgery, the release said. That study is more than 80% enrolled.

“As we continue to advance the OBG platform towards commercialization, we continue to actively consider all strategic alternatives to maximize shareholder value,” Stephen From, EyeGate CEO, said in the release.